Get the Stockscreener App
55.64
0.11%
-0.23
Revolution Medicines Inc stock is traded at $55.64, with a volume of 371.68K.
It is down -0.11% in the last 24 hours and up +17.94% over the past month.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
See More
Previous Close:
$55.87
Open:
$55.62
24h Volume:
371.68K
Relative Volume:
0.36
Market Cap:
$9.32B
Revenue:
$29.52M
Net Income/Loss:
$-484.27M
P/E Ratio:
-17.07
EPS:
-3.26
Net Cash Flow:
$-457.88M
1W Performance:
+10.69%
1M Performance:
+17.94%
6M Performance:
+38.83%
1Y Performance:
+151.84%
1-Day Range:
$54.97
$56.00
1-Week Range:
$49.92
$56.56
52-Week Range:
$18.79
$56.56
Revolution Medicines Inc Stock (RVMD) Company Profile
Name
Revolution Medicines Inc
Sector
Industry
Phone
415-766-3638
Address
700 SAGINAW DR, REDWOOD CITY, CA
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-16-24 | Reiterated | Needham | Buy |
| Jul-12-24 | Initiated | Barclays | Overweight |
| Jul-08-24 | Initiated | Jefferies | Buy |
| Apr-12-24 | Reiterated | Needham | Buy |
| Apr-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-04-24 | Initiated | Wedbush | Outperform |
| Nov-16-23 | Initiated | Raymond James | Outperform |
| Feb-28-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-14-22 | Initiated | Needham | Buy |
| Oct-21-22 | Initiated | Oppenheimer | Outperform |
| May-20-22 | Initiated | BofA Securities | Neutral |
| Mar-01-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Aug-12-21 | Downgrade | Goldman | Buy → Neutral |
| May-18-21 | Initiated | Goldman | Buy |
| May-21-20 | Initiated | H.C. Wainwright | Buy |
| Mar-09-20 | Initiated | Cowen | Outperform |
| Mar-09-20 | Initiated | Guggenheim | Buy |
| Mar-09-20 | Initiated | JP Morgan | Neutral |
View All
Revolution Medicines Inc Stock (RVMD) Latest News
Revolution Medicines to Participate in Upcoming Investor Conferences - The Manila Times
Revolution Medicines Inc (RVMD) Q3 2024 Earnings Report Preview: What To Look For - GuruFocus.com
Revolution Medicines' SWOT analysis: cancer drug developer's stock potential - Investing.com India
Revolution Medicines' SWOT analysis: cancer drug developer's stock potential By Investing.com - Investing.com UK
Brokerage firm bumps Revolution Medicines stock PT on positive trial data - Investing.com UK
Revolution Medicines (NASDAQ:RVMD) Given New $60.00 Price Target at Oppenheimer - Defense World
Revolution Medicines (RVMD) Set to Announce Earnings on Wednesday - MarketBeat
Allspring Global Investments Holdings LLC Raises Stock Position in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024 - The Manila Times
Revolution Medicines stock hits 52-week high at $51.01 - Investing.com
Revolution Medicines stock hits 52-week high at $51.01 By Investing.com - Investing.com UK
Raymond James & Associates Purchases 116,135 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
China Universal Asset Management Co. Ltd. Purchases 12,744 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Revolution Medicines (NASDAQ:RVMD) PT Raised to $82.00 - MarketBeat
Revolution Medicines Targets Hard-to-Treat Pancreatic Cancer With Two Early-Phase Readouts - BioSpace
Revolution Medicines reports positive RMC-9805 study results - Investing.com India
Revolution Medicines reports positive RMC-9805 study results By Investing.com - Investing.com Australia
Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma - The Manila Times
Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with - The Bakersfield Californian
Revolution Medicines Presents Initial Data from RMC-9805 - GlobeNewswire
Needham & Company LLC Reaffirms Buy Rating for Revolution Medicines (NASDAQ:RVMD) - MarketBeat
(RVMD) On The My Stocks Page - Stock Traders Daily
Revolution Medicines reports progress in pancreatic cancer study By Investing.com - Investing.com Australia
Revolution Medicines (NASDAQ:RVMD) Shares Up 3.2%Still a Buy? - MarketBeat
Revolution Medicines reports progress in pancreatic cancer study - Investing.com India
Revolution Medicines Presents Updated Data from RMC-6236 - GlobeNewswire
Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma - Yahoo Finance
Head to Head Comparison: Revolution Medicines (NASDAQ:RVMD) vs. Fresh Tracks Therapeutics (NASDAQ:FRTX) - Defense World
Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma - BioSpace
Revolution Medicines Announces First Patient Dosed in Phase - GlobeNewswire
Revolution Medicines, Inc. (NASDAQ:RVMD) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Revolution Medicines executive sells $824,804 in stock - Investing.com India
Revolution Medicines executive sells $824,804 in stock By Investing.com - Investing.com South Africa
Revolution Medicines (NASDAQ:RVMD) Sets New 12-Month HighTime to Buy? - MarketBeat
Insider Selling: Revolution Medicines, Inc. (NASDAQ:RVMD) Insider Sells 16,666 Shares of Stock - MarketBeat
Revolution Medicines COO Margaret Horn sells $2.52m in stock - Investing.com India
Revolution Medicines COO Margaret Horn sells $2.52m in stock By Investing.com - Investing.com South Africa
Revolution Medicines CEO sells $1.51 million in stock By Investing.com - Investing.com Australia
Revolution Medicines, Inc. (NASDAQ:RVMD) General Counsel Jeff Cislini Sells 6,000 Shares - MarketBeat
Revolution Medicines CFO Jack Anders sells shares worth $502,979 - Investing.com India
Revolution Medicines CFO Jack Anders sells shares worth $502,979 By Investing.com - Investing.com Australia
Revolution Medicines' general counsel sells $301,026 in stock By Investing.com - Investing.com Canada
Revolution Medicines CEO sells $1.51 million in stock - Investing.com India
Revolution Medicines' general counsel sells $301,026 in stock - Investing.com India
AQR Capital Management LLC Purchases New Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Check Out Revolution Medicines Inc (RVMD)’s Trade Data Rather Than the Analysts’ Views - SETE News
An Analysis of Revolution Medicines Inc (RVMD)’s Potential Price Growth - Knox Daily
Trend Tracker for (RVMD) - Stock Traders Daily
Revolution Medicines, Inc. (NASDAQ:RVMD) Stock Holdings Lifted by Creative Planning - MarketBeat
Revolution Medicines Inc Stock (RVMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):